key: cord-0740642-mm31azyp authors: Yazdanpanah, Yazdan title: Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients date: 2020-11-10 journal: J Med Virol DOI: 10.1002/jmv.26601 sha: 8574bc48a4bcf3220c6736115aebb6cadf6bdb95 doc_id: 740642 cord_uid: mm31azyp Little is known on the association between clinical factors and coronavirus disease 2019 (COVID‐19) more than 15 days after diagnosis. We conducted a multicentric prospective cohort of COVID‐19 hospitalized patients to describe clinical, biological, and virological characteristics at hospital admission and over time, according to mortality up to Day 60 after admission. For the analysis of risk factors of survival, analyses assessing associations between mortality and demographic characteristics or comorbidities were performed using a Cox regression model. Between January 24 and March 15, 2020, 246 patients with reverse‐transcriptase polymerase chain reactions virologically confirmed COVID‐19 were enrolled. In multivariate analysis, mortality at Day 60 (n = 42 patients, 17.1% [95% confidence interval, 12.6–22.4]) was associated with older age (adjusted hazard ratio [aHR] for age ≥ 65 years: 5.22 [2.56–10.63, p < .001]), gender (aHR for male: 2.97 [1.47–5.99, p = .002]), chronic pulmonary disease (aHR: 4.84 [2.32–10.07, p < .001]), obesity (aHR: 3.32 [1.70–6.52, p < .001]), and diabetes (aHR: 1.98 [1.01–3.89, p = .048]). The median nasopharyngeal viral load at admission was 6.4 log(10) copies/ml and was associated with mortality regardless of clinical risk factors. Viral load decreased with time elapsed since symptoms onset. Our study confirmed that mortality was associated with clinical characteristics at admission. The viral load at admission was significantly lower in patients admitted late after the onset of symptoms in both dead and alive patients. Our results could improve earlier identification of patients with increased risk of mortality and adapted management. In France, the first confirmed case-a Chinese tourist-was reported on January 14th, 2020. 2 As an attempt to contain the virus spread, all patients with confirmed COVID-19 were admitted to hospital, regardless of their medical condition. By March 15th, 6378 confirmed cases were reported in France, with a doubling time of 48 h. As of March 15th, admission to hospital was based on the medical condition and patients with mild symptoms were no longer hospitalized. The national prospective French COVID cohort was initiated end-January and enrolled hospitalized patients in various centers across mainland France and overseas territories. The cohort collects systematic clinical, biological, radiological, and virological data during hospitalization, as well as after discharge. Here, we describe the clinical, biological, and virological characteristics at admission and during the first 60 days after admission in all patients enrolled up to March 15th, 2020. Hospitalized patients with a virologically confirmed COVID-19 were enrolledin the French COVID cohort (registered in clinicaltrials.gov NCT04262921). The study was conducted with the understanding and the consent of each participant or its surrogate. The study was sponsored by Inserm and Ethics approval was given by the French Ethics Committee CPP-Ile-de-France VI (ID RCB: 2020-A00256-33). All patients enrolled until March 15 th , 2020 were analyzed. Nasopharyngeal swabs were performed on the day of admission for SARS-CoV-2 testing according to WHO or French National Health Agency guidelines. 3 Viral loads were quantified by real-time semiquantitative reverse-transcriptase polymerase chain reactions (RT-PCR), using either the Charité WHO protocol (testing E gene and RdRp), or the Pasteur institute assay (testing E gene and two other RdRp targets, IP2 and IP4). 4, 5 When several assays were available, the IP4 Ct value was used as a reference. Results provided in cycle threshold (Ct) were transformed to log 10 RNA copies/ml, using the relationship assessed by Pasteur Institute for both genes. 5 Data were collected through the French-modified version, the openaccess Case Report Form of the International Severe Acute Respiratory and Emerging Infection Consortium. 6 Baseline laboratory and radiological findings were recorded within the first 3 days of hospitalization. Clinical, biological, radiological, virological data, and outcomes were assessed during hospitalization. Patients were followed up 2/4 weeks after discharge and at 3 months postadmission. The primary objectives of this study were to describe the baseline clinical, biological, and radiological characteristics of virologicalconfirmed patients with COVID-19 at admission, to describe their evolution in the 60 days after admission, and to compare these variables between dead and alive patients. Continuous variables were described as medians and interquartile ranges [IQR] . Categorical variables were described as numbers of patients (percentages). The number of available data for each variable was given. For the analysis of risk factors of survival, univariate analyses assessing associations between mortality and demographic characteristics or comorbidities were performed using a Cox regression model. Patients discharged alive were censored at the first date between the date of their last follow-up (date of discharge or date of visit 2-4 weeks after discharge) and the date of administrative censoring (Day 60). Variables with less than 10% of missing values and with p < .20 in univariate analysis were tested in multivariate models. The variable selection was performed using a stepwise backward multivariate Cox regression with a p-value cutoff point of .05. Two-way interactions between risk factors kept in the multivariate analysis were tested. The association between viral load (available on a subset of the population) and survival was assessed in a Cox regression multivariate model adjusted on the risk factors identified in the previous multivariate model. All tests were twosided and analyses were performed with SAS software (SAS V9.4). We assessed the association between viral load at admission and the time since symptoms onset in both dead and alive patients (Spearman's correlation). To account for potential heterogeneity in the viral load detection, patients with Ct more than 37 were considered undetectable. T A B L E 1 Demographic, clinical, radiologic, and biologic characteristics at admission of the first 246 patients enrolled in the French COVID cohort (44) Chronic pulmonary disease (not asthma) 246 21/246 (9) 12/175 (7) 9/71 (13) Asthma 246 23/246 (9) 14/175 (8) 7/71 (10) Chronic kidney disease 246 16/246 (7) 7/175 (4) 9/71 (13) Chronic liver disease 245 9/245 (4) 8/175 (5) 1/70 (1) Chronic neurological disorder 246 18/246 (7) 10/175 (6) 8/71 (11) Malignant neoplasm 245 14/245 (6) 11/175 (6) 3/70 (4) Chronic hematologic disease 246 8/246 (3) 6/175 (3) 4/71 (6) AIDS/HIV 74 0/74 (0) 0/50 (0) (3) Wheezing 229 15/229 (7) 6/171 (4) 9/58 (16) Chest pain 231 22/231 (10) 18/172 (10) 4/59 (7) Myalgia 232 (5) Altered consciousness/confusion 238 11/238 (5) 6/175 (3) 5/63 (8) Seizures (0) Abdominal pain 235 14/235 (6) 8/172 (5) 6/63 (10) Vomiting/nausea 238 26/238 (11) 19/174 (11) 7/64 (11) Diarrhea 239 45/239 (19) 34/173 (20) 11/66 (17) Conjunctivitis 237 4/237 (2) 4/173 (2) 0/64 (0) Skin rash 239 4/239 (2) 2/175 (1) 2/64 (3) Skin ulcers 201 0/201 (0) 0/155 (0) 0/46 (0) Lymphadenopathy 235 3/235 (1) 2/172 (1) 1/63 (2) Anosmia 109 5/109 (5) 4/76 (5) 1/33 (3) Ageusia 110 4/110 (4) 3/77 (4) 1/33 (3) Hemorrhage 238 (2) 2/127 (2) 1/62 (2) Adenovirus 212 0/162 (0) 0/103 (0) 0/59 (0) Bacteria 168 10/168 (6) 4/106 (4) 6/62 (10) Viral load (log 10 copies/ml) 184 6. The median age was 62 years (IQR, 50-73), with 106 (43%) aged 65 years or older, and the proportion of males was 57%. The proportion of patients having at least one comorbidity was 38%, in particular hypertension (30%), other chronic cardiovascular diseases (20%), obesity (17%), and diabetes (16%). The proportion of current smokers was 8%. The proportion of healthcare workers or working in a microbiology laboratory was 9%. The median number of days between the onset of clinical symptoms until hospital admission was 7 days. [5] [6] [7] [8] [9] [10] [11] The four most common symptoms at admission were a history of fever, faintness, shortness of breath, and myalgia. Chest x-ray at admission was abnormal in 75% of the patients, with bilateral abnormalities in 82% of them. Laboratory findings at the admission are summarized in Table 1. 3.2 | Follow-up and outcome at Day 60 postadmission in alive patients at D60 and 18/41 in dead patients at D60). Figure 2 shows the evolution of selected clinical and biological parameters. Patients who subsequently died had higher heart and respiratory rates at admission, and these values continued to increase during follow-up as compared with alive patients. Likewise, C-reactive protein (CRP), blood urea nitrogen, and white blood cells count increased more rapidly during the first week of hospitalization in patients who subsequently died than in those who survived. Hemoglobin decreased rapidly in the first week of follow-up while platelet count sharply dropped later on in patients who subsequently died compared to those who survived. We compared baseline demographic and comorbidities between dead (n = 42) and alive (n = 204) patients. In univariate analysis ( There was no significant two-way interaction among those factors. Viral load at admission was associated with mortality adjusted on the previous five clinical risk factors (Table S1 ). A total of 351 nasopharyngeal viral load data were obtained from 159 patients, with 35 dead patients and 124 alive patients at Day 60 ( Figure 3A ). The median viral load at admission was 6.4 log 10 copies/ ml [IQR, . The viral load at admission was significantly lower in patients admitted late after the onset of symptoms in both dead and alive patients (p = .06 and P < 10 −4 , respectively, Figure 3B ). In this prospective clinical cohort, we described the clinical, biological, and virological characteristics at admission and during the first 60 days of hospitalization in all patients enrolled up to March 15th, 2020. Other studies comparing characteristics of patients with and without severe diseases have been published recently in larger populations, in particular in the United States and in China. 7, 8 However, these studies were mostly retrospective or studies in which data were collected retrospectively, and many of these data were restricted to critical or severe patients, with a short-term follow-up and no data on viral load kinetics. For example, a retrospective report was published on more than 1500 patients in Lombardia, Italy, but this study only included ICU patients. 9 In the present study, we prospectively enrolled patients with a wide range of disease severity status: patients who did not medically require hospitalization but who were hospitalized to avoid disease transmission in the community, patients who required hospitalization but who were not admitted to ICU, and those admitted to ICU. This allows us to evaluate characteristics associated with mortality and with a preplanned and prospective collection of biological and virological data. The mortality rate at Day 60 was 17.1% [12.6%-22 .4%], which is lower than in larger series, such as those published from New York City area (21%) 8 and Wuhan (28%). 10 Also, in the RECOVERY trial, overall 28-day mortality was 25.7% in the usual care group. 11 This might be due, in part, to the enrollment of patients with mild COVID-19 disease who were hospitalized at the very beginning of the epidemic in France. Indeed, again in the RECOVERY trial, 28-day mortality was 17.8% and 14.0% for the dexamethasone group and the usual care group, respectively, in patients who did not require oxygen at the time of randomization. 11 Interestingly, the mortality rate was 10.2% [6.7-14.6] at Day 14 and rose up to 17.1% [12.6-22.4 (3.3% [1.4-6.3] , and four were still hospitalized in ICU (1.6% [0.4-4.1] ). CI, confidence interval; ICU, intensive care unit with prevalence rates of 30.6% and 15.7%, respectively. 12, 13 Accordingly, the prevalence of diabetes (16%) was close to that in the general population, with a prevalence of 16% as compared with 20% in men aged between 75 and 85 years in the French general population. 14 The proportion of current smokers was equal to 8%, which is much lower than in the French general population, in the range 25%-30%. 15 This proportion is nonetheless highly agedependent and falls to 20% in people aged between 55 and 64 years, and to 10% in those aged between 65 and 75 years. 15 Age, male gender, chronic pulmonary disease (not asthma), obesity, and diabetes were associated with mortality, in line with previous reports. 8, 10 Cardiovascular comorbidities, such as chronic cardiac disease, were associated with mortality in the univariate analysis but not in the multivariate analysis, possibly due to confounding factors, such as obesity and diabetes. We compared the dynamics of clinical and biological variables over time in dead and alive patients. An increase in respiratory rate, in heart rate and/or biological parameters, in particular CRP, white blood count, and in blood urea nitrogen, and a drop in platelet count were early predictive markers of subsequent death and could be useful in the future to guide clinicians. 10 One of the strengths of this cohort was to collect nasopharyngeal viral load measurements at admission and prospectively. (7) 5/42 (12) 1.66 (0.65-4.23) .29 Abbreviation: COVID, coronavirus disease. a HR: hazard ratios of the association of each factor with mortality. rate: median (IQR), breaths per min Systolic blood pressure: median (IQR), mmHg Diastolic blood pressure: median (IQR), mmHg and the French COVID cohort investigators group (for inclusion of participants, follow-up and local laboratory) (by alphabetical order Cécile FICKO, Marie GOMINET, Aurore BOUSQUET (Hôpital d'instruction des armées Begin) Ségolène GREFFE Simon BESSIS Grand Hôpital de l'Est Francilien site Marne-la-Vallée Simon-Djamel THIBERVILLE Eric DELAVEUVE, Coline JAUD François BIS-SUEL A novel coronavirus from patients with pneumonia in China Clinical and virological data of the first cases of COVID-19 in Europe: a case series WHO. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans Protocol: real-time RT-PCR assays for the detection of SARS-CoV-2 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Open source clinical science for emerging infections Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Dexamethasone in hospitalized patients with Covid-19: preliminary report Prévalence du surpoids, de l'obésité et des facteurs de risque cardio-métaboliques dans la cohorte Constances prévalence, traitement et contrôle en 2015 et évolutions depuis 2006 Prévalence du diabète traité pharmacologiquement (tous types) en France en 2015. Disparités territoriales et socio-économiques Baisse de la prévalence du tabagisme quotidien parmi les adultes: résultats du Baromètre de Santé publique Pr. Yazdanpanah reports no conflict of interest. http://orcid.org/0000-0001-9445-1117